




The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Net Income, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 88%, being 127% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	318
Liabilities, Non-Current	0
Other Assets	1,146
Other Compr. Net Income	0
Other Expenses	17
Other Liabilities	0
Other Net Income	3.6
Other Revenues	0
Property and Equipment	0
Research and Development	726
Selling, General and Administrative Expense	2,847

Output Variable	Value in 1000 USD
Assets	1,146
Liabilities	318
Expenses	3,590
Revenues	0
Stockholders Equity	827
Net Income	-3,586
Comprehensive Net Income	-3,586
BaseVar	2,529
ECR before Limited Liability	-244%
Economic Capital Ratio	88%